X4 Pharmaceuticals, Inc.
XFOR
$3.18
$0.3813.57%
NASDAQ
06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
---|---|---|---|---|---|
Revenue | 5,721.31% | -- | -- | -- | -- |
Total Other Revenue | -- | -- | -- | -- | -- |
Total Revenue | 5,721.31% | -- | -- | -- | -- |
Cost of Revenue | 1,978.73% | -- | -- | -- | -- |
Gross Profit | 9,121.36% | -- | -- | -- | -- |
SG&A Expenses | 13.49% | 29.33% | 73.27% | 75.17% | 62.30% |
Depreciation & Amortization | -- | -- | -- | -- | -- |
Other Operating Expenses | -- | -- | -- | -- | -- |
Total Operating Expenses | 11.68% | 25.46% | 33.89% | 22.34% | 23.13% |
Operating Income | 14.33% | 1.69% | -31.51% | -21.30% | -22.57% |
Income Before Tax | -673.29% | 111.58% | 63.26% | 84.99% | 113.59% |
Income Tax Expenses | 258.33% | 249.46% | 297.44% | 44.07% | 380.00% |
Earnings from Continuing Operations | -678.36% | 111.32% | 62.98% | 84.92% | 113.52% |
Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
Minority Interest in Earnings | -- | -- | -- | -- | -- |
Net Income | -678.36% | 111.32% | 62.98% | 84.92% | 113.52% |
EBIT | 14.33% | 1.69% | -31.51% | -21.30% | -22.57% |
EBITDA | 15.15% | 2.44% | -31.28% | -21.30% | -22.76% |
EPS Basic | -671.05% | 110.85% | 69.37% | 89.36% | 108.26% |
Normalized Basic EPS | -12.50% | 35.87% | -17.38% | 23.50% | 58.10% |
EPS Diluted | -680.37% | 110.72% | 69.23% | 89.19% | 108.12% |
Normalized Diluted EPS | -12.53% | 35.89% | -17.36% | 23.52% | 58.11% |
Average Basic Shares Outstanding | 4.42% | 5.88% | 13.20% | 30.63% | 59.66% |
Average Diluted Shares Outstanding | 4.48% | 6.04% | 13.25% | 30.69% | 59.73% |
Dividend Per Share | -- | -- | -- | -- | -- |
Payout Ratio | -- | -- | -- | -- | -- |